Advent Bioservices

Executive Summary

Advent Bioservices is a UK-based Contract Development and Manufacturing Organisation (CDMO) specialised in cell and gene therapies, founded in 2017 and headquartered in Cambridge. The company is developing a state-of-the-art, multiproduct GMP manufacturing facility to address the growing demand for advanced therapy medicinal product (ATMP) production. Advent offers end-to-end services including process development, GMP manufacturing, quality control, and regulatory support, positioning itself as a key partner for biotech and pharmaceutical companies seeking to bring cell and gene therapies to market. With the global ATMP market expanding rapidly, Advent's timely facility build-out and expertise in complex biologics manufacturing provide a strong growth trajectory. The company's strategy focuses on capturing outsourced manufacturing demand from developers lacking in-house capacity. While still in a development phase, Advent's location in Cambridge's biotech cluster and its experienced team underpin its potential to become a leading European CDMO for advanced therapies. Key near-term value drivers include facility completion and securing initial client contracts.

Upcoming Catalysts (preview)

• Q4 2026Completion of GMP manufacturing facility70% success
• H1 2027First commercial manufacturing contract50% success
• TBDStrategic partnership or collaboration with a major biotech40% success